Gapping up
In reaction to earnings/guidance:
- RDNT +5.7%, XPEV +2.4%
Other news:
- OPGN +21.4% (announces publication of of a new peer-reviewed publication on the Unyvero Hospitalized Pneumonia panel in hospitalized patients with COVID-19 pneumonia)
- ATH +17.4% (Athene Holding and Apollo (APO) to merge in an all-stock transaction that implies a total equity value of approximately $11 billion for Athene)
- ADPT +11.2% (receives FDA Emergency Use Authorization for T-Detect COVID to confirm recent or prior COVID-19 infection)
- MCFE +10.9% (to sell its Enterprise business to a consortium led by Symphony Technology Group (STG) in an all-cash transaction for $4.0 billion, expects to issue a $4.50 special dividend )
- ARDS +9.4% (has augmented its inhaled AR-711 monoclonal antibody to COVID-19 with a second mAb that is designed to neutralize newly emerging COVID-19 mutated variants including those from South Africa, Brazil and Japan)
- AGLE +9% (Baker Bros Advisors disclose 9.9% stake)
- NHIC +6.9% (Evolv Technology to become publicly traded through merger with NewHold Investment Corp)
- CARA +5.3% (Vifor Pharma and Cara Therapeutics announce FDA acceptance and Priority Review of NDA for KORSUVA injection in hemodialysis patients with moderate-to-severe pruritus)
- SRNE +4.2% (Lee's Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer )
- LGHL +3.9% (signed engagement letters with Maxim Group LLC and Loeb & Loeb LLP to form a second SPAC company, Aquarius I Acquisition Corp)
- VXX +3.3% (trading higher with early weakness in stock indices)
- PASG +2.9% (receives Fast Track Designation to three passage bio gene therapy candidates targeting rare CNS disorders)
- NBA +2.4% (Airspan Networks to go public through merger with New Beginnings Acquisition Corp)
- COHR +2% (Coherent determines IIVI's proposal to be superior to Lumentum (LITE) merger agreement)
- OCGN +1.9% (new presentation slides)
Analyst comments:
- AMRX +5.1% (upgraded to Buy from Sell at Goldman)
- WTRH +4.7% (upgraded to Buy from Hold at Deutsche Bank)
- DSP +4.7% (initiated with a Buy at Needham)
- IOVA +3.2% (upgraded to Buy from Neutral at H.C. Wainwright)
- ZTS +2.6% (upgraded to Buy from Neutral at BofA Securities)
- KO +0.8% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- TGT +0.8% (upgraded to Buy from Neutral at Guggenheim)